Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 6/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16775659 | 0.85 | CYP19A1 (0.48) | CYP19A1ABCB1MAOBCYP26A1L3MBTL1 | |
| SCHEMBL16193647 | 0.84 | CYP19A1 (0.50) | CYP19A1ABCB1MAOBCYP26A1L3MBTL1 | |
| SCHEMBL16201907 | 0.83 | HTR1A (0.44) | CYP19A1MAOBMEN1KMT2A | |
| SCHEMBL16194380 | 0.82 | CYP19A1 (0.49) | CYP19A1ABCB1MEN1KMT2AALDH1A1 | |
| SCHEMBL5952468 | 0.80 | ACHE (0.41) | CYP19A1MAOBMEN1KMT2AALDH1A1 | |
| SCHEMBL1583277 | 0.80 | METAP1 (0.42) | CYP19A1 | |
| SCHEMBL6717685 | 0.79 | PARP10 (0.42) | CYP19A1CYP26A1 | |
| SCHEMBL16775664 | 0.78 | CYP19A1 (0.45) | CYP19A1ABCB1MAOBCYP26A1L3MBTL1 | |
| SCHEMBL16201914 | 0.78 | CYP19A1 (0.39) | CYP19A1ABCB1MAOBCYP26A1MEN1 | |
| SCHEMBL5951367 | 0.77 | HTR1A (0.42) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9415027-B2 | Therapeutic agents | ALLERGAN, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-20150258048-A1 | THERAPEUTIC AGENTS | ALLERGAN, INC. | 2015-09-17 | — | — | US | disclosed |
| US-9051294-B2 | Therapeutic agents | ALLERGAN, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-20140323558-A1 | THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323558-A1 | THERAPEUTIC AGENTS | PTGER4, PTGER2, PTGER1 | CYP19A1 2330/4885ABCB1 2632/4885CES2 1983/4885 |
| US-20150258048-A1 | THERAPEUTIC AGENTS | PTGER4, PTGER2, PTGER1 | CYP19A1 2330/4885ABCB1 2632/4885CES2 1983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.